Position in ROIV
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$58,181
-$13,634,605 QoQ
Shares Held
1,644
-99.7% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#381
of 494 holders
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in ROIV Over Time
Shares Held
Position Value (USD)
Derivatives in ROIV
reported options exposure · as of Dec 31, 2025CallValue
$972,160
CallShares
44,800
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026TORONTO DOMINION BANK holds $769,395,513 across 60 Biotechnology names. ROIV ranks #33 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PTCT |
Ptc Therapeutics, Inc.
|
2,165,846 | $176,668,057 | |
| 2 | CELC |
Celcuity Inc.
|
1,258,758 | $131,691,261 | |
| 3 | STOK |
Stoke Therapeutics, Inc.
|
3,173,258 | $103,829,001 | |
| 4 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
181,432 | $97,419,912 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
85,391 | $42,416,270 | |
| 6 | TARS |
Tarsus Pharmaceuticals, Inc.
|
510,253 | $32,115,323 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
48,783 | $30,418,151 | |
| 8 | NGNE |
Neurogene Inc.
|
681,337 | $21,428,048 |
All Filings in ROIV
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $58,181 | 1,644 | Shares | Defined | 2026-08-14 | |
| 2025-12-31 | $972,160 | 44,800 | Call | Defined | 2026-02-17 | |
| 2025-12-31 | $13,692,786 | 631,004 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $24,208 | 1,600 | Put | Defined | 2025-11-14 | |
| 2025-09-30 | $24,208 | 1,600 | Call | Defined | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||